share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  2024/09/09 18:15

Moomoo AI 已提取核心信息

NeuroSense Therapeutics has successfully completed the in-life phase of its nine-month non-rodent toxicity study for drug candidate PrimeC. The study, which was initiated in November 2023 following discussions with the U.S. Food and Drug Administration (FDA) regarding trial design, has yielded positive results.The successful completion of this toxicity study aligns with the company's regulatory strategy and provides further validation of PrimeC's long-term safety profile, marking a significant milestone in the drug's development pathway.
NeuroSense Therapeutics has successfully completed the in-life phase of its nine-month non-rodent toxicity study for drug candidate PrimeC. The study, which was initiated in November 2023 following discussions with the U.S. Food and Drug Administration (FDA) regarding trial design, has yielded positive results.The successful completion of this toxicity study aligns with the company's regulatory strategy and provides further validation of PrimeC's long-term safety profile, marking a significant milestone in the drug's development pathway.
NeuroSense Therapeutics成功完成了其九个月非啮齿动物毒性研究的在研阶段,该研究针对药物候选PrimeC。该研究于2023年11月在与美国食品药品监督管理局(FDA)讨论试验设计后启动,取得了积极的结果。这一毒性研究的成功完成与公司的监管策略一致,并进一步验证了PrimeC的长期安全性,标志着该药物开发过程中的一个重要里程碑。
NeuroSense Therapeutics成功完成了其九个月非啮齿动物毒性研究的在研阶段,该研究针对药物候选PrimeC。该研究于2023年11月在与美国食品药品监督管理局(FDA)讨论试验设计后启动,取得了积极的结果。这一毒性研究的成功完成与公司的监管策略一致,并进一步验证了PrimeC的长期安全性,标志着该药物开发过程中的一个重要里程碑。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息